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Letter to the Editor
Response to Torrance et al. [Osteoarthritis and Cartilage 2002; 10:518–27]
I applaud the effort of Torrance et al. for their outcomes
studies of the intra-articular hyaluronan injections in the
treatment of osteoarthritis (OA) of the knee1,2. These
analyses of the cost-effectiveness and impact on quality of
life fill a gap in available information regarding therapeutic
approaches to the management of OA of the knee. While a
number of studies have evaluated the economic and
quality-of-life outcomes using analgesics or nonsteroidal
anti-inflammatory agents (NSAIDs), there is very little data
pertaining to intra-articular hyaluronan therapy.
I have several comments regarding the economic analy-
ses and model. First, the appropriate care (AC) treatment
of OA based on ACR guidelines employs COX-2-specific
inhibitors or NSAIDs with a gastro-protective agent3. Inclu-
sion of these oral agents may have a profound impact on
the economic model for chronic management of OA of the
knee. Second, it is puzzling that the appropriate care plus
hylan (AC+H) treated group, compared with the AC alone
group, has lower NSAID costs yet slightly higher costs of
treating adverse events due to concomitant OA medica-
tions (e.g., antacids, analgesics). Hospitalization costs
were also higher for the AC+H group, as were the costs for
essentially every category of indirect costs (i.e., time lost
from work and transportation costs).
Although substantial evidence supports the safety of
hyaluronan therapy, a number of adverse reactions specifi-
cally associated with hylan G-F 20 have been reported.
These reports include documented pseudoseptic (syno-
vitis) adverse reactions4–8, soft tissue inflammatory
reactions9–11, and one report of six cases of granulomatous
inflammation of the synovium, all following intra-articular
hylan G-F 20 injections12. A recent study estimates that
adverse reactions to hylan G-F 20 affect about 2% of the
patients following an initial course of therapy and as much
as 21% of patients following a repeat cycle13.
The adverse reactions associated with intra-articular
injections though generally infrequent14, may affect both
direct and indirect (disability, work time, and quality of life
lost) healthcare costs. It is not clear if Torrance and
coworkers have considered the potentially significant medi-
cal costs associated with the management of these ad-
verse reactions in clinical practice and/or hospital
settings13–14 as well as the indirect costs of these adverse
reactions as part of the projected cost of hylan G-F 20
therapy. These costs may not apply to economic models of
other hyaluronan therapy products, for which similarly high
prevalence of adverse reactions have not been reported.
Nevertheless, the authors have provided important in-
sight into the economic considerations and comprehensive
treatise of OA management.
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